Ann: Starpharma and Medicxi Partnership Petalion Therapeutics, page-156

First 156 Last

Share
Profile

Follow
Starlink

999 Posts.

185

06/07/24

10:02

Post #: 74635338
Share

Originally posted by bid: ↑

The chance Petalion achieve success somewhere between 3.5 and 4 out of 5 IMO. The Medicxi model for funding is staged and closely monitored. Progress payments are forwarded based on likelihood success, and also consideration is weighted as to how early stage the project is before coming to them for funding/investment.
Spl dendrimer platform is now well tested. The parameters/limitations are well known. SPL have been working with dendrimers for near two decades. Starpharma are one of only two companies to have successfully monetised therapy using dendrimers. The poly lysine dendrimer is the least toxic. Starpharma have proved they can manufacture at scalability and consistency, safety, tolerability and purity problems have been solved. They are not a startup. The platform DEP is now well proven.
The petalion initiative is looking to develop a treatment modality in oncology therapy for where there is unmet need. So a broad range of indications will be tested for probable success. Starpharma will be paid for the work they do to conjugate drugs for testing. This three way Starpharma Petalion Medicxi arrangement is ideal. Medicxi closely monitor likelihood of success and extend funding based on this. They can kill a project pretty quickly, which is good as you don’t want to waste time on poor prospects. But where our platform being further down the pipeline weight is given to that and can let trials run longer to give it a chance. Modern day drug developers use computational modeling and AI which can be pretty powerful tools in drug modeling to determine likelihood success to then determine worthiness progress tested in the clinic. Petalion would no doubt employ these technologies. They’ve been searching for a good while looking for the perfect partner with a platform that is Starpharmas DEP. It’s a good arrangement, will further validate our platform at no risk to us. It wasn’t our initiative but if they succeed we have a stake in that success. Nothing ventured nothing gained. IMO. I am not a scientist or physician. DYOR.

Expand

IMHO
UK has had the wars - BREXIT and the PANDEMIC and now they have a new government of intelligent reconstruction. SPL partnering with Medicxi “in” Petalion is a great opportunity to be part of the reconstruction wave in a country 3 times the size of Australia.

SPL Price at posting: 9.9¢ Sentiment: Buy Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

There are more pages in this discussion • 6 more messages in this thread...

First 156 Last

Add SPL (ASX) to my watchlist

(20min delay)
Last 9.7¢		Change 0.000(0.00%)		Mkt cap ! $40.06M

Open	High	Low	Value	Volume
9.5¢	9.7¢	9.5¢	$2.069K	21.46K

Buyers (Bids)

No.	Vol.	Price($)
1	3987	9.7¢

Sellers (Offers)

Price($)	Vol.	No.
9.8¢	5206	2

View Market Depth

No.	Vol.	Price($)
1	3987	0.097
2	19275	0.096
4	318851	0.095
4	360000	0.094
2	9659	0.093

Price($)	Vol.	No.
0.098	5206	2
0.099	2373	1
0.100	34876	2
0.105	209291	3
0.110	168286	9

Last trade - 13.56pm 07/10/2024 (20 minute delay)

SPL (ASX) Chart

Ann: Starpharma and Medicxi Partnership Petalion Therapeutics, page-156

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Starpharma and Medicxi Partnership Petalion Therapeutics, page-156

Top Stories

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News